Selank

What the Russian clinical literature shows

• · Russian-language clinical studies, primarily conducted at institutes under the Russian Academy of Sciences, reported anxiolytic-like effects in human participants with generalised anxiety and neurasthenia diagnoses.
• · Animal studies reported effects on brain enkephalin and monoamine levels in rodent models.
• · The compound achieved Russian pharmaceutical registration, which required the submission of clinical dossiers to Russian regulatory authorities.
• · The Russian clinical data does exist in peer-reviewed form (some papers translated into or published in English), but the trials were generally small, conducted at a single site, and used methodological designs that would not meet current FDA, EMA, or MHRA randomised controlled trial standards.
• · Russian pharmaceutical registration is not equivalent to, and does not confer, EU or UK marketing authorisation. MHRA and EMA assess compounds through their own independent submission and review processes.
• · Wide availability in Russian pharmacies is a consequence of domestic regulatory approval. It does not constitute evidence of efficacy by western regulatory standards.

Sister compound: Semax (see Semax encyclopedia entry) is a separate Russian-developed peptide with a different mechanism and target indication, often paired with Selank in research discussions.